Hi Col
"I wonder how much sway (if any) Vanderbilt University Medical Centres would have with BARDA ? We are still looking at COVID-19 ARDS as well as all cause ARDS so maybe BARDA will throw us a few sheckles ?"
Let's not forget our recently appointed director Dr Philip Krause may also have some sway with BARDA (and NIH).
IMO Covid (and all cause) ARDS trial with Vanderbelt will not commence until Rem-L potency assays are given the green light by FDA. We shall know soon enough
RWE for 2nd MSB COVID-19 ARDS P3 Trial, page-878
-
- There are more pages in this discussion • 28 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
-0.055(4.66%) |
Mkt cap ! $1.293B | |||
| Open | High | Low | Value | Volume |
| $1.18 | $1.18 | $1.13 | $4.824M | 4.236M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 25589 | $1.13 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 10000 | 1 |
View Market Depth
| Last trade - 16.10pm 17/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |